Psychiatry Research最新文献

{"title":"Latent classes of acute grief reactions in the shadow of collective trauma and its predictors in bereaved adults","authors":"Yaira Hamama-Raz,&nbsp;Menachem Ben-Ezra,&nbsp;Yafit Levin","doi":"10.1016/j.psychres.2024.116331","DOIUrl":"10.1016/j.psychres.2024.116331","url":null,"abstract":"<div><div>The current study explored grief reaction profiles after the October 7th, 2023, Israeli massacre regarding the loss of significant others. It investigated factors worsening pre-existing grief in 2,028 adult civilians, with 1,263 reporting pre- or post-massacre loss. Participants completed self-reports on prolonged grief disorder (PGD), post-traumatic stress disorder (PTSD), complex PTSD (CPTSD), cognitive emotional regulation (CER), and assumptive worldviews. Latent class analysis identified four classes of probable PGD among those with lifetime loss: \"high PGD—both core and emotional pain\" (35.9 %); \"Medium PGD—emotional pain\" (6.9 %); \"medium to high PGD—high core, medium emotional pain\" (23 %); and \"low PGD—both core and emotional pain\" (34.5 %). The subsample analysis of individuals experiencing lifetime loss with concurrent October 7th loss indicated three classes of probable PGD: \"high PGD symptoms\" (47.9 %), \"high to medium PGD—high core with medium emotional pain symptoms\" (15.9 %), and “low PGD symptoms” (36.2 %). The subsample analysis of those who experienced concurrent recent loss related to the October 7th attack showed two classes related to indicative of acute grief: \"high PGD symptoms” (69 %), and “low PGD symptoms” (31 %). Negative CER coping strategies were associated significantly with the high PGD in all three groups, and with increased risk of PTSD and CPTSD symptoms compared to the \"low PGD symptoms\" group. Collective bereavement amid collective trauma can activate prior individual grief reactions, even without current losses from the traumatic event. Those experiencing loss tied to severe traumatic events may face higher susceptibility to developing pathological grief.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116331"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Tribute to Timothy J. Crow: 1938–2024","authors":"Lynn E. DeLisi","doi":"10.1016/j.psychres.2024.116300","DOIUrl":"10.1016/j.psychres.2024.116300","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116300"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative administration of esketamine during cesarean section is a double-edged sword","authors":"Takahiko Nagamine","doi":"10.1016/j.psychres.2024.116321","DOIUrl":"10.1016/j.psychres.2024.116321","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116321"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of bright light therapy improves outcomes of perinatal depression: A systematic review and meta-analysis of randomized controlled trials","authors":"Lian Du ,&nbsp;Jinkun Zeng ,&nbsp;Hua Yu ,&nbsp;Bijun Chen ,&nbsp;Wei Deng ,&nbsp;Tao Li","doi":"10.1016/j.psychres.2024.116303","DOIUrl":"10.1016/j.psychres.2024.116303","url":null,"abstract":"<div><div>The efficacy of bright light therapy (BLT) in the context of perinatal depression remains underexplored. This meta-analysis aimed to systematically assess the effectiveness of BLT among perinatal depression. A comprehensive literature search was performed across several databases, including the Cochrane Central Register of Controlled Trials, PubMed, Embase, CNKI and the clinical trials registry platform, covering the period from the inception of each database up to January 2024. The Cochrane Collaboration's bias assessment tool was employed to evaluate the quality of the included studies. Review Manager 5.3 Software was utilized to conduct the meta-analysis. Six trials, encompassed a total of 167 participants diagnosed with perinatal depression were incorporated quantitative analysis, all of those have been published in English, with no restriction on publication year, and used BLT and dim light therapy (DLT) as intervention. The relative risk (<em>RR</em>) of BLT compared to DLT for perinatal depression is 1.46 (fixed effects model, <em>p</em> = 0.04, 95 % <em>CI</em> = [1.02, 2.10]), indicating a significant improvement in depression outcomes compared to DLT groups. The heterogeneity test yielded an <em>I²</em> value of 41 % (<em>p</em> = 0.13), indicated a low degree of heterogeneity. Considering the small sample size, we conducted a sensitivity analysis, found <em>RR</em> increased to 2.33 (fixed effects model, <em>p</em> = 0.001, <em>CI</em> = 1.39–3.92). Cochrane Risk of Bias Tool showed only a single study was deemed high quality. This study indicates a beneficial impact of BLT on perinatal depression, subgroup analysis finds no significant mediation effects of different parameters after sensitivity analyses. It is recommended that future studies with larger samples be conducted to explore the effects of BLT on perinatal depression.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116303"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials","authors":"Damian Swieczkowski ,&nbsp;Aleksander Kwaśny ,&nbsp;Michal Pruc ,&nbsp;Zuzanna Gaca ,&nbsp;Lukasz Szarpak ,&nbsp;Wiesław J. Cubała","doi":"10.1016/j.psychres.2024.116337","DOIUrl":"10.1016/j.psychres.2024.116337","url":null,"abstract":"<div><div>Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of Randomized Placebo-Controlled Clinical Trials (RCTs) registered with PROSPERO was conducted. Databases searched included Embase, PubMed, Cochrane Library, Scopus, Web of Science, and Google Scholar, up to July 2024. The PICOS framework defined eligibility criteria: P: adult patients with MDD; I: psilocybin; C: placebo; O: changes in MADRS scores at Days 2, 8 and 15, and adverse events; S: RCT. Independent researchers performed data extraction and bias assessment. From 5419 search results, three RCTs involving 389 patients were included. Psilocybin significantly reduced symptoms compared to placebo at Day 8 (MD = -7.42; 95 % CI:10.07 to -4.78; <em>p</em> &lt; 0.001) and Day 15 (MD = -9.55; 95 % CI:12.44 to -6.65; <em>p</em> &lt; 0.001), without significant effects on Day 2. The NMA indicated that a 25 mg dose was the most effective, with a SUCRA value of 92.25 %, compared to doses of 0.215 mg/kg and 10 mg. However, psilocybin was associated with a higher risk of adverse events, particularly nausea (RR = 8.35; <em>p</em> &lt; 0.001). This meta-analysis supports psilocybin's efficacy in treating MDD, particularly at a 25 mg dose, showing a time-dependent therapeutic effect. The recommended timing of efficacy evaluation by regulatory authorities is validated by this evidence, underscoring its importance in clinical trial design for psychedelic substances.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116337"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The unfolding of psychological distress following the October 7 attack on Israel: The impact of exposure, gender, and event centrality","authors":"Eva Gilboa Schechtman ,&nbsp;Dan E. Hay ,&nbsp;Itai Schwartz ,&nbsp;Yuval Neria ,&nbsp;David Roe","doi":"10.1016/j.psychres.2025.116356","DOIUrl":"10.1016/j.psychres.2025.116356","url":null,"abstract":"<div><h3>Background</h3><div>Mass disasters, whether natural or human-made, pose significant public health challenges, with some individuals demonstrating resilience, whereas others experience persistent emotional distress that may meet diagnostic criteria for mental health disorders. We explored key risk factors for distress following the October 7, 2023, Hamas attacks on Israel, focusing on trauma exposure, gender, and event centrality.</div></div><div><h3>Method</h3><div>A longitudinal study design was used, assessing posttraumatic distress (PTSD), depression, generalized anxiety, event centrality, and functioning at approximately three (T1; <em>n</em>=858) and seven (T2, <em>n</em>=509) months post-attack.</div></div><div><h3>Results</h3><div>Replicating findings from war trauma literature, we documented a high comorbidity among PTSD, depression, and anxiety; greater distress in women; and a dose-response relationship between exposure and distress. Event centrality was consistently linked to distress at both time points. Extending the literature, we found that gender, exposure, and event centrality contributed to distress at each time point. Moreover, important gender-specific patterns of risk and distress were revealed. In addition, distress at T1, event centrality at T1, gender, and continuous exposure contributed to distress at T2. Whereas distress and event centrality remained stable, functioning improved significantly from T1 to T2, highlighting the different trajectories of distress and recovery.</div></div><div><h3>Conclusions</h3><div>Personalized approaches and continuous monitoring of individuals exposed to cumulative trauma are highlighted. The importance of assessing multiple indices of trauma – distress, functioning, and meaning –to address mental health needs in the wake of mass disasters is emphasized.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116356"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of internet-delivered universal and tailored transdiagnostic interventions for anxiety and depression: A systematic review and meta-analysis of randomized controlled trials","authors":"JiaLi Liu ,&nbsp;ChaoYang Li ,&nbsp;YuFei Qiu ,&nbsp;YiQing Yu ,&nbsp;LiJuan Zeng ,&nbsp;Man Wu ,&nbsp;YangYang Han ,&nbsp;Fen Yang","doi":"10.1016/j.psychres.2024.116324","DOIUrl":"10.1016/j.psychres.2024.116324","url":null,"abstract":"<div><h3>Background</h3><div>Internet-delivered transdiagnostic psychological interventions are promising approaches for the treatment of anxiety and depression. This study aimed to review and synthesize evidence related to the effectiveness of Internet-based transdiagnostic interventions for reducing anxiety and depression, and to compare the effects of universal versus tailored interventions.</div></div><div><h3>Methods</h3><div>A Systematic review search was conducted on the PubMed, EMBASE, Cochrane Library, Web of Science, PsychINFO, Medline, and CINAHL databases as of 28 March 2024. Two researchers made their choices based on consensus. This study performed a random-effects meta-analysis comparing patients receiving Internet-based transdiagnostic therapy with a control group, and examined the effects on depression, anxiety, and quality of life. This meta-analysis compared the effect of Internet-delivered universal and tailored transdiagnostic on anxiety and depression.</div></div><div><h3>Results</h3><div>42 trials were identified with a total of 4982 participants. Compared with the control group, the Internet-delivered transdiagnostic intervention reduced anxiety and depression symptoms (<em>g</em> = −0.617, 95 % CI: −0.699 to −0.535), anxiety (<em>g</em> = −0.580, 95 % CI: −0.690 to −0.470), depression (<em>g</em> = −0.650, 95 % CI: −0.770 to −0.530). The Internet-delivered universal transdiagnostic treatment was more effective than tailored transdiagnostic in improving anxiety and depression. Internet-delivered transdiagnostic interventions also had a positive impact on quality of life (<em>g</em> = 0.310; 95 % CI: 0.130 to 0.490).</div></div><div><h3>Conclusions</h3><div>This meta-analysis demonstrates that Internet-based transdiagnostic interventions are effective for treating anxiety and depression, and can also improve quality of life. The universal Internet-delivered transdiagnostic intervention is better than the tailored intervention. Future studies should investigate the mechanisms of change and develop outcome measures for these interventions.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116324"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of internet-based cognitive behavioral therapy for medicated adults with attention-deficit/hyperactivity disorder (ADHD): A randomized controlled trial","authors":"Shi-Yu Zhang ,&nbsp;Mei-Rong Pan ,&nbsp;Li-Qian Zhang ,&nbsp;Hai-Mei Li ,&nbsp;Meng-Jie Zhao ,&nbsp;Min Dong ,&nbsp;Fei-Fei Si ,&nbsp;Lu Liu ,&nbsp;Yu-Feng Wang ,&nbsp;Qiu-Jin Qian","doi":"10.1016/j.psychres.2025.116352","DOIUrl":"10.1016/j.psychres.2025.116352","url":null,"abstract":"<div><h3>Background</h3><div>Cognitive behavioral therapy (CBT) is an effective treatment for adults with attention-deficit/hyperactivity disorder (ADHD), but its use is limited by poor accessibility and time constraints—barriers that internet-based CBT (iCBT) may help overcome. This trial aimed to explore the short- and long-term efficacy of iCBT in medicated adults with ADHD.</div></div><div><h3>Methods</h3><div>Eighty-six adults with ADHD were randomized into two groups: the iCBT combined with medication group (iCBT+<em>M, n</em> = 43) and the medication-only group (<em>n</em> = 43). The iCBT+<em>M</em> group received 12 weeks of iCBT with ongoing medication, while the medication-only group continued with medication alone. The primary outcome was the change in ADHD symptoms. Secondary outcomes included emotional symptoms, executive function, quality of life, and global functioning. Outcomes were assessed at baseline, post-treatment (T1), 6-month (T2), and 12-month follow-up (T3). Mixed linear models were used to assess the differences in outcomes between the two groups at each follow-up point.</div></div><div><h3>Results</h3><div>Compared to the medication-only group, the iCBT+<em>M</em> group showed greater improvements in ADHD symptoms (<em>d</em> = 0.50 at T1/T2, 0.59 at T3), executive function (<em>d</em> = 0.87 at T1, 0.49 at T2, 0.25 at T3), quality of life (<em>d</em> = -0.74 at T1, -0.59 at T2, -0.28 at T3), global functioning (<em>d</em> = 0.66 at T1, 0.85 at T2, 0.42 at T3), and anxiety (<em>d</em> = 0.43 at T1).</div></div><div><h3>Conclusion</h3><div>iCBT interventions may benefit medicated adults with ADHD by improving core symptoms, executive function, quality of life, and overall functioning, with effects sustained for 12 months.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116352"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep and physical activity patterns in relation to daily-life symptoms in psychosis: An actigraphy and experience sampling study","authors":"Lydia E. Pieters ,&nbsp;Jeroen Deenik ,&nbsp;Adriaan W. Hoogendoorn ,&nbsp;Eus J.W. van Someren ,&nbsp;Peter N. van Harten","doi":"10.1016/j.psychres.2024.116320","DOIUrl":"10.1016/j.psychres.2024.116320","url":null,"abstract":"<div><div>Sleep disturbances and reduced physical activity (PA) are important risk factors for poor physical and mental health outcomes in people with psychosis. However, the precise interrelations between sleep, PA and psychopathology remain unclear. This study combined experience sampling (ESM) and actigraphy in thirty-two patients with a schizophrenia spectrum disorder to investigate interrelations of day-to-day variations in actigraphic estimates of PA and sleep and psychotic and affective symptoms. Multilevel mixed-models show that subjects reported more positive affect on more physically active days. Unexpectedly, participants reported worse next-day negative affect and/or psychotic symptoms after nights with higher sleep continuity, as consistently indicated by sleep efficiency and the mean duration of bouts of wake and sleep. Lastly, PA was higher after nights with higher sleep continuity and shorter total sleep duration. These results highlight that modifiable lifestyle factors such as PA and sleep have an intricate, but clinically relevant relationship with psychotic and affective symptoms. Future studies are needed to further examine the complex effects of these behaviors in order to develop effective, targeted treatment strategies to improve clinical outcome in psychosis.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116320"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of implementation science in major depressive disorder: A narrative review","authors":"Yuru He ,&nbsp;Jill K. Murphy ,&nbsp;Xing Wang ,&nbsp;Erin E. Michalak ,&nbsp;Tao Yang ,&nbsp;Xiaorui Yang ,&nbsp;Jing Liu ,&nbsp;Yiru Fang ,&nbsp;Raymond W. Lam ,&nbsp;Jun Chen","doi":"10.1016/j.psychres.2024.116330","DOIUrl":"10.1016/j.psychres.2024.116330","url":null,"abstract":"<div><div>Major depressive disorder (MDD) is one of the most prevalent and disabling mental disorders with high recurrence rate. There is often a gap between scientific evidence related to the effective and cost-effective treatment of depression and clinical practice. Implementation science is a field of inquiry that aims to advance the process of applying evidence-based interventions to real-world problems. Implementation research consists of two broad phases. The first phase seeks to identify the gaps that exist between evidence and practice and their impact on outcomes. The second phase, building on the first, evaluates the effectiveness of implementation strategies by examining various implementation indicators to support the adoption and scale up of interventions. Although implementation research can facilitate the uptake and adoption of evidence-based interventions, it is underused in depression research. In this narrative review, the authors will introduce the definition of implementation science and the state of implementation science in MDD in order to support more widespread use of implementation science for scaling up evidence-based interventions.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"344 ","pages":"Article 116330"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}